Abe Naomichi, Kato Sayuka, Tsuchida Takuma, Sugimoto Kanami, Saito Ryuta, Verschuren Lars, Kleemann Robert, Oka Kozo
Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda-shi, Saitama 335-8505, Japan
Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda-shi, Saitama 335-8505, Japan.
Biol Open. 2019 May 1;8(5):bio041251. doi: 10.1242/bio.041251.
Non-alcoholic steatohepatitis (NASH) is a fast-growing liver disease in the Western world. Currently, only a few animal models show both the metabolic and histological features of human NASH. We aimed to explore murine NASH models in a time dependent manner that exhibit metabolic, histological and transcriptomic hallmarks of human NASH. For this, the murine strains C57BL/6J, ob/ob, and KK-A were used and three types of nutritional regimes were administered: normal chow diet (NCD); high-fat, high-fructose, and high-cholesterol diet (fast food diet; FFD); or choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD), for 2, 4, 8, 12, 18, 24, and 30 weeks. All strains under the FFD and CDAHFD regimes developed steatohepatitis. Among the strains treated with FFD, the non-alcoholic fatty liver disease (NAFLD) activity score, fibrosis progression and metabolic abnormalities such as hyperinsulinemia and obesity were more pronounced in ob/ob mice than in C57BL/6J and KK-A mice. In ob/ob mice fed FFD, the development of hepatic crown-like structures was confirmed. Furthermore, molecular pathways involved in steatohepatitis and fibrosis showed significant changes from as early as 2 weeks of starting the FFD regime. Ob/ob mice fed FFD showed metabolic, histological, and transcriptomic dysfunctions similar to human NASH, suggesting their potential as an experimental model to discover novel drugs for NASH.
非酒精性脂肪性肝炎(NASH)在西方世界是一种快速发展的肝脏疾病。目前,只有少数动物模型同时具备人类NASH的代谢和组织学特征。我们旨在以时间依赖性方式探索表现出人类NASH代谢、组织学和转录组学特征的小鼠NASH模型。为此,使用了小鼠品系C57BL/6J、ob/ob和KK-A,并给予三种营养方案:正常饲料饮食(NCD);高脂肪、高果糖和高胆固醇饮食(快餐饮食;FFD);或胆碱缺乏、L-氨基酸限定的高脂肪饮食(CDAHFD),持续2、4、8、12、18、24和30周。在FFD和CDAHFD方案下的所有品系都发展出了脂肪性肝炎。在接受FFD治疗的品系中,ob/ob小鼠的非酒精性脂肪性肝病(NAFLD)活动评分、纤维化进展以及高胰岛素血症和肥胖等代谢异常比C57BL/6J和KK-A小鼠更为明显。在喂食FFD的ob/ob小鼠中,证实了肝冠样结构的形成。此外,早在开始FFD方案的2周起,参与脂肪性肝炎和纤维化的分子途径就显示出显著变化。喂食FFD的ob/ob小鼠表现出与人类NASH相似的代谢、组织学和转录组功能障碍,表明它们作为发现NASH新药的实验模型的潜力。